Management Devices for Tinnitus | NYU Langone Health
Doctors at NYU Langone use hearing aids and masking and retraining devices to help people manage tinnitus.
Management of Vaginal Precancerous Lesions | NYU Langone Health
NYU doctors may prescribe topical chemotherapy or perform laser surgery to manage precancerous lesions of the vagina.
Managing End-Stage Kidney Disease in Children with Chronic Kidney Disease | NYU Langone Health
Kidney experts at Hassenfeld Children’s Hospital at NYU Langone recommend kidney transplantation for children with end-stage kidney disease.
Managing Oral Precancerous Growths | NYU Langone Health
NYU Langone doctors may observe or surgically remove an oral precancerous growth.
Managing Precancerous Oropharyngeal Growths | NYU Langone Health
NYU Langone doctors may observe or surgically remove precancerous oropharyngeal growths.
Manhattan Locations | NYU Langone Health
See all NYU Langone locations in Manhattan and find locations in your neighborhood.
Marfan Syndrome | NYU Langone Health
Doctors at NYU Langone are experts in treating Marfan syndrome, which can affect the heart, bones, eyes, lungs, and nervous system.
Master protocol of two independent randomized double-blind Phase 3 studies comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis.
This clinical trial aims to assess the effectiveness and safety of an investigational drug, frexalimab, for treating relapsing multiple sclerosis (RMS). Frexalimab works by targeting and blocking the CD40 ligand (CD40L) protein, which plays a key role in the immune system's response to infection. In MS, the immune system mistakenly attacks the brain, leading to lesions and disability. The study will compare the efficacy and safety of frexalimab to the FDA-approved drug teriflunomide (Aubagio). Participants will be randomly assigned to receive either frexalimab (with placebo) or teriflunomide (with placebo) for up to 40 months. Frexalimab will be administered intravenously every 4 weeks, while teriflunomide is taken orally once a day. The study will evaluate relapse rates, disease progression, brain lesions through MRI, and overall safety of the treatments.
Maternal–Fetal Medicine at NYU Langone Obstetrics & Gynecology Associates | NYU Langone Health
Doctors at Maternal–Fetal Medicine at NYU Langone Obstetrics and Gynecology Associates care for women experiencing high-risk pregnancies.
Maternal–Fetal Medicine at NYU Langone Obstetrics & Gynecology Associates Doctors | NYU Langone Health
Find a doctor at Maternal–Fetal Medicine at NYU Langone Obstetrics & Gynecology Associates.